干扰Hedgehog/GLI信号通路靶向血液系统恶性肿瘤的癌症标志性弱点
本综述聚焦Hedgehog(HH)/GLI通路在多发性骨髓瘤、T细胞和B细胞淋巴瘤及淋系和髓系白血病等血液系统恶性肿瘤中的特异性作用。通过总结经典与非经典、不依赖Smoothened的HH/GLI信号及临床前体内外研究,阐明该通路调控细胞增殖、癌症干细胞命运、基因组不稳定、微环境重塑和细胞存活等癌症标志的分子机制,并汇总现有HH抑制剂临床试验的成败与未来联合治疗机会。
要点
- HH/GLI信号通路在多种血液系统恶性肿瘤中调控增殖、干细胞命运、基因组不稳定、微环境重塑和存活等癌症标志。
- 综述涵盖经典与非经典、不依赖Smoothened的HH/GLI信号及血液肿瘤中的临床前体内外研究。
- 全面理解HH/GLI信号对癌症标志形成的广泛致癌效应,有助于识别肿瘤细胞及其重塑微环境中的关键弱点,为新型高效个体化联合治疗铺路。
核心结论
- 全面理解HH/GLI信号对癌症标志形成的广泛致癌效应,对于识别肿瘤细胞及其支持性重塑微环境中的关键弱点至关重要,可为血液系统恶性肿瘤开发新型高效的个体化联合治疗铺平道路。
研究设计与样本
- 综述,聚焦HH/GLI通路在多发性骨髓瘤、T细胞和B细胞淋巴瘤以及淋系和髓系白血病等血液系统恶性肿瘤中的特异性作用。
- 综述了经典与非经典、不依赖Smoothened的HH/GLI信号,并总结了血液系统恶性肿瘤中的临床前体外和体内研究。
- 汇总了当前HH抑制剂的临床试验,并讨论了成功与挑战以及未来联合治疗策略的机会。
主要发现
- HH/GLI信号控制细胞增殖、癌症干细胞命运、基因组不稳定、微环境重塑和细胞存活等关键致癌过程和癌症标志。
- 综述阐明了HH/GLI信号在血液系统恶性肿瘤中控制上述癌症标志的常见分子机制。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Understanding the genetic alterations, disrupted signaling pathways, and hijacked mechanisms in oncogene-transformed hematologic cells is critical for the development of effective and durable treatment strategies against liquid tumors. In this review, we focus on the specific involvement of the Hedgehog (HH)/GLI pathway in the manifestation and initiation of various cancer features in hematologic malignancies, including multiple myeloma, T- and B-cell lymphomas, and lymphoid and myeloid leukemias. By reviewing canonical and noncanonical, Smoothened-independent HH/GLI signaling and summarizing preclinical in vitro and in vivo studies in hematologic malignancies, we elucidate common molecular mechanisms by which HH/GLI signaling controls key oncogenic processes and cancer hallmarks such as cell proliferation, cancer stem cell fate, genomic instability, microenvironment remodeling, and cell survival. We also summarize current clinical trials with HH inhibitors and discuss successes and challenges, as well as opportunities for future combined therapeutic approaches. By providing a bird's eye view of the role of HH/GLI signaling in liquid tumors, we suggest that a comprehensive understanding of the general oncogenic effects of HH/GLI signaling on the formation of cancer hallmarks is essential to identify critical vulnerabilities within tumor cells and their supporting remodeled microenvironment, paving the way for the development of novel and efficient personalized combination therapies for hematologic malignancies.
引用
- Krenn PW, Aberger F. Targeting cancer hallmark vulnerabilities in hematologic malignancies by interfering with Hedgehog/GLI signaling. Blood. 2023. PMID: 37595276. doi:10.1182/blood.2021014761
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。